SEC Form 4 · accession 0001140361-15-028636

ANGIODYNAMICS INC · ANGO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Jul 22, 2015

Accepted (ET)

Jul 24, 2015 · 9:28 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001275187

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 22, 2015	A	28,061	$0.00	A	207,241	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F2	$15.95	Jul 22, 2015	A	96,251	A	Jul 22, 2016	Jul 22, 2022	Common Stock	96,251	96,251	D
Performance Right^F3	—	Jul 22, 2015	A	37,414	A	—	—	Common Stock	37,414	37,414	D

F11. This acquisition of 28,061 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents 28,061 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 22, 2016, such that 25% of the restricted stock units will vest on each of July 22, 2016, 2017, 2018 and 2019.
F2These stock options vest in four equal annual installments beginning on July 22, 2016, such that 25% of the options will vest on each of July 22, 2016, 2017, 2018 and 2019.
F3Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period covering the Company's fiscal years 2016, 2017 and 2018. Any shares that do not vest at the end of the performance period will be forfeited.